Cloudbreak

Antibacterial Program

Cloudbreak Antibacterial Fc Conjugates (ABCs) may offer several benefits over small molecule approaches against multi-drug resistant (MDR) bacterial infections.

Cloudbreak

Antibacterial Program

Cloudbreak Antibacterial Fc Conjugates (ABCs) may offer several benefits over small molecule approaches against multi-drug resistant (MDR) bacterial infections.

Cloudbreak Antibacterial Program

Our Cloudbreak conjugates are potent, long acting, and bi-specific biologics designed to simultaneously target and destroy the pathogen while directing and enhancing the immune response at the site of infection.

Potential Advantages of Antibacterial Fc Conjugates (ABCs)

  • Direct kill: Novel TMs tightly bind LPS and kill bacteria – KAPE spectrum
  • Immunomodulatory: Fc engages and initiates an immune system response
  • Superior half-life/ADME: Antibody-like PK, receptor mediated transport to lung, limited toxicity
  • Potentiation: Enhances permeability of standard of care therapeutics to provide additional efficacy
  • Protection from septic shock: Attenuation of sepsis response through LPS scavenging
1
Direct kill: novel TMs tightly bind LPS and kill bacteria – KAPE spectrum
2
Immunomodulatory: Fc recruits and initiates an innate immune system response
3
Superior PK/ADME: Antibody-like PK, receptor mediated transport to lung, limited kidney exposures
4
Potentiation: Enhances permeability of standard of care therapeutics to provide additional efficacy
5
Protection from septic shock: Attenuation of sepsis response through LPS scavenging

Gram-negative Bacterial Infections

According to data from the U.S. National Healthcare Safety Network, Gram-negative pathogens are responsible for greater than 30% of all healthcare associated infections (HAIs) and about 70% in intensive care units (ICUs). The CDC estimates that there were 1.7 million HAIs in the U.S. and the estimated number of death associated with HAIs were 99,000, costing the U.S. health care system $20B per year. While mortality due to these infections is already high, infections caused by MDR strains result in significantly higher mortality and hospital length of stay when compared to those caused by susceptible strains.

While new antibiotics introduced over the past 15 years have made significant progress in the fight against resistant Gram-positive bacteria, including MRSA (Methicillin-resistant staphylococcus aureus), a recent CDC report highlighted the urgent need for novel antibacterials that are effective against Gram-negative bacteria, particularly carbapenem-resistant Enterobacteriaceae (CRE), MDR-Acinetobacter baumannii and Pseudomonas aeruginosa. Several recently approved or late-stage antibacterials provide adequate coverage of less resistant forms of CRE and P. aeruginosa, but significant spectrum gaps remain.

Immunocompromised patients are at significantly higher risk of developing a MDR Gram-negative infection and have inadequate immune systems to adequately fight the infections. Novel ABCs are needed that provide both an antibacterial effect in addition to leveraging the remaining immune system to help clear the infection. New resistance mechanisms, such as the emergence of the mcr-1 resistance gene have rendered even toxic last line treatments ineffective.

Mortality Rate by Susceptibility of Pathogen

Mortality rates are much higher in patients with resistant bacteria compared to susceptible strains.

GET IMPORTANT NEWS AND UPDATES BY EMAIL